Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.
Times cited: 38
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
Times cited: 100
Celiac disease and irritable bowel-type symptoms.
The American journal of gastroenterology.
Times cited: 109